Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial-Reference-Cited by-同舟云学术

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

Published:2019-11 Issue:11 Volume:20 Page:1506-1517
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Kato Ken,Cho Byoung Chul,Takahashi Masanobu,Okada Morihito,Lin Chen-Yuan,Chin Keisho,Kadowaki Shigenori,Ahn Myung-Ju,Hamamoto Yasuo,Doki Yuichiro,Yen Chueh-Chuan,Kubota Yutaro,Kim Sung-Bae,Hsu Chih-Hung,Holtved Eva,Xynos Ioannis,Kodani Mamoru,Kitagawa Yuko

Publisher

Elsevier BV

Subject

Oncology

Reference32 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Epidemiology of esophageal squamous cell carcinoma;Abnet;Gastroenterology,2018

3. Integrated genomic characterization of oesophageal carcinoma;Nature,2017

4. Comparative molecular analyses of esophageal squamous cell carcinoma, esophageal adenocarcinoma, and gastric adenocarcinoma;Salem;Oncologist,2018

5. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Lordick;Ann Oncol,2016

Cited by 850 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapeutic strategies in gastroesophageal tumors;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

2. Berbamine promotes ferroptosis of esophageal squamous cell carcinoma by facilitating USP51-mediated GPX4 ubiquitination and degradation;Biomedicine & Pharmacotherapy;2024-10

3. Impact of baseline steroids on the efficacy of neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma;World Journal of Gastrointestinal Oncology;2024-09-15

4. The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy;Current Treatment Options in Oncology;2024-09-11

5. Immunotherapy as a new perspective for the therapy of esophageal cancer;Innovative Surgical Sciences;2024-09-09